Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial

BACKGROUND: Cardiogenic shock (CS) is associated with significant morbidity and mortality. The impact of beta-blocker (BB) use on patients who develop CS remains unknown. We sought to evaluate the clinical outcomes and hemodynamic response profiles in patients treated with BB in the 24 h prior to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Santo, Pietro, Mathew, Rebecca, Jung, Richard G., Simard, Trevor, Skanes, Stephanie, Mao, Brennan, Ramirez, F. Daniel, Marbach, Jeffrey A., Abdel-Razek, Omar, Motazedian, Pouya, Parlow, Simon, Boczar, Kevin E., D’Egidio, Gianni, Hawken, Steven, Bernick, Jordan, Wells, George A., Dick, Alexander, So, Derek Y., Glover, Christopher, Russo, Juan J., McGuinty, Caroline, Hibbert, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356445/
https://www.ncbi.nlm.nih.gov/pubmed/34376218
http://dx.doi.org/10.1186/s13054-021-03706-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356445/
https://www.ncbi.nlm.nih.gov/pubmed/34376218
http://dx.doi.org/10.1186/s13054-021-03706-2

Ejemplares similares